Aditya Bardia, MD, MPH, FASCO

Aditya Bardia, MD, MPH, FASCO, is a professor in the Department of Medicine, Division of Hematology/Oncology and director of Translational Research Integration at UCLA Health Jonsson Comprehensive Cancer Center.

Articles

HR+ Metastatic Breast Cancer: Optimal Selection of Endocrine Partners

March 9th 2023

Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.

Advice for Community Physicians on Managing HER2+ Breast Cancer

March 7th 2023

Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.

Continuing CDK4/6 Inhibition at Progression of HR+ Metastatic Breast Cancer

March 2nd 2023

Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.

Molecular Testing in Relapsed/Refractory HR+ Metastatic Breast Cancer

March 2nd 2023

A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.

Potential Role for T-DXd in Early-Stage HER2-Low Breast Cancer

February 28th 2023

Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.

Optimizing Real-World Management of HER2-Low Breast Cancer

February 28th 2023

Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.

Factors in Selecting 1L Therapy for Patients With HR+ Metastatic Breast Cancer

February 23rd 2023

Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.

HR+ Metastatic Breast Cancer: Molecular Profiling and 1L Treatment Approaches

February 23rd 2023

Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.

Expert Perspectives on Defining HER2-Low Breast Cancer

February 21st 2023

Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.

Overview on Treatment Options for HER2+ Breast Cancer

February 21st 2023

Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.

How Clinical Trials Inform Treatment Selection in Early-Stage HR+ Breast Cancer

February 16th 2023

A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.

Early-Stage HR+ Breast Cancer: Ki67 and the monarchE Trial

February 16th 2023

Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.

How Ki67 Informs Use of Therapy in Early-Stage HR+ Breast Cancer

February 9th 2023

A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.

Best Practices for Molecular Testing in Early-Stage Breast Cancer

February 9th 2023

Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.

Dr. Bardia on the FDA Approval of Sacituzumab Govitecan in HR+/HER2– Metastatic Breast Cancer

February 8th 2023

Aditya Bardia, MD, MPH, discusses the significance of the FDA approval of sacituzumab govitecan in patients with pretreated hormone receptor–positive, HER2-negative metastatic breast cancer and key data from the phase 3 TROPiCS-02 trial.

Dr. Bardia on the Ongoing Investigation of Oral SERDs in ER+/HER2- Breast Cancer

December 19th 2022

Aditya Bardia, MD, MPH, discusses the investigation of oral selective estrogen receptor degraders in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Dr. Bardia on Elacestrant in ER+/HER2– Metastatic Breast Cancer

December 8th 2022

Aditya Bardia, MD, MPH, discusses the use of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Future Treatment Strategies for Triple-Negative Breast Cancer

September 19th 2022

Closing out his discussion on the management of metastatic triple-negative breast cancer, Aditya Bardia, MD, MPH, considers future treatment strategies that may improve outcomes for patients.

First-Line Treatment for Metastatic TNBC: Pembrolizumab + Chemotherapy

September 19th 2022

Comprehensive insight on use of first-line pembrolizumab plus chemotherapy in patients diagnosed with metastatic TNBC based on results from the KEYNOTE-355 trial.

Patient Scenario: A 44-Year-Old Woman With Metastatic TNBC

September 13th 2022

Centering discussion on a patient scenario of metastatic TNBC, Aditya Bardia, MD, MPH, highlights the value of first-line chemoimmunotherapy as a treatment option.